HuMAB-5B1-ATAC

N/A

Report date: 2025/03/20 16:01:40

Base Information

Drug NameHuMAB-5B1-ATAC
Drug Alias Name5B-1-guided antibody drug conjugate (MabVax/Heidelberg Pharma)5B1 sialyl-lewis A antibody drug conjugate (MabVax Therapeutics Holdings/Heidelberg Pharma)HuMab 5B1-ADC5B-1-guided ADC (MabVax/Heidelberg Pharma)amanitin-5B1 antibody drug conjugate (Heidelberg Pharma)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPancreatic NeoplasmsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMabvax Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMabvax Therapeutics Holdings IncHeidelberg Pharma AG
Inactive CompaniesMabvax Therapeutics Inc
Active IndicationsPancreatic Neoplasms
Inactive IndicationsColonic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A